New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:11 EDTTGTX, LGNDTG completes global license agreement with Ligand for IRAK4
TG Therapeutics (TGTX), announced an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. The IRAK4 program is currently in pre-clinical development. Under the terms of the agreement, Ligand will receive an up-front licensing fee of 125k unregistered shares of TG Therapeutics' common stock. In addition, TG will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales.
News For TGTX;LGND From The Last 14 Days
Check below for free stories on TGTX;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
08:03 EDTLGNDGlaxoSmithKline receives FDA approval for sNDA for Promacta/Revolade
Ligand Pharmaceuticals Incorporated (LGND) announced that its partner GlaxoSmithKline (GSK) has received approval of a supplemental New Drug Application for the once-daily use of Promacta/Revolade in patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells and platelets.2 Eltrombopag, an oral thrombopoietin receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.
August 25, 2014
11:45 EDTLGNDLemelson says Ligand has 'lost favor with largest investors'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use